Part 2: Patient information, informed decision-making and the psycho-social impact of prostate-specific antigen testing

BJU International, Supplement

Volumn 95, Issue 3, 2005, Pages 16-32

  Hewitson, Paul ^a   Austoker, Joan ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Decision aids; Decision making; Informed choice; Mass screening; Patient information; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SCREENING; DECISION MAKING; INFORMED CONSENT; MEDICAL INFORMATION; PATIENT INFORMATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOCIAL PSYCHOLOGY;

ADULT; AGED; ANXIETY; COUNSELING; DECISION MAKING; HUMANS; INFORMED CONSENT; MALE; MASS SCREENING; MIDDLE AGED; PATIENT EDUCATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; RISK FACTORS; TREATMENT OUTCOME; VIDEOTAPE RECORDING;

EID: 17444408102     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. National Health Service Cancer Screening Programmes. Aim of prostate cancer risk management 2004. http:// www.cancerscreening.nhs.uk/prostate/ pcrm-aim.html. Accessed 25-10-2004
2. Department of Health. Prostate cancer information sheet. 2004 http:// www.doh.gov.uk/cancer/prostate.htm. Accessed 25-10-2004
3. National Electronic Library for Health. Screening: prostate cancer 2004 http:// nelh.nhs.uk/screening/adult_pps/ prostate_cancer.html: Accessed 25-10-2004
4. National Health Service Cancer Screening Programmes. Information pack for primary care 2004 http:// www.cancerscreening.nhs.uk/prostate/ informationpack.html. Accessed 25-10-2004
5. O'Connor AM, Stacey D, Rovner D et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2001; 3: CD001431
6. Montgomery AA, Fahey T, Peters TJ. A factorial randomised controlled trial of decision analysis and an information video plus leaflet for newly diagnosed hypertensive patients. Br J General Pract 2003; 53: 446-53
7. Garrud P, Wood M, Stainsby L. Impact of risk information in a patient education leaflet. Patient Educ Couns 2001; 43: 301-4
8. General Medical Council. Seeking patients' consent: the ethical considerations. London: General Medical Council, 1998
9. Demark-Wahnefried W1 Strigo T, Catoe K et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology 1995; 46: 346-51
10. Diefenbach PN, Ganz PA, Pawlow AJ, Guthrie D. Screening by the prostate-specific antigen test. What do the patients know? J Cancer Educ 1996; 11: 39-44
11. O'Dell KJ, Volk RJ, Cass AR, Spann SJ. Screening for prostate cancer with the prostate-specific antigen test: are patients making informed decisions? J Fam Pract 1999; 48: 682-8
12. Schulman CC, Kirby R, Fitzpatrick JM. Awareness of prostate cancer among the general public: findings of an independent international survey. Eur Urol 2003; 44: 294-302
13. Smith RA, Mettlin CJ, Davis KJ, Eyre H. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2000; 50: 34-49
14. Carroll P, Coley C, McLeod D et al. Prostate-specific antigen best practice policy - Part I. Early detection and diagnosis of prostate cancer. Urology 2001; 57: 217-24
15. Carroll P, Coley C, McLeod D et al. Prostate-specific antigen best practice policy - Part II. Prostate cancer staging and post-treatment follow-up. Urology 2001; 57: 225-9
16. Canadian Urological Association. PSA. 1992. http://www.cua.org. Accessed 25-10-2004
17. Canadian Urological Association. Guidelines for the Early Detection of Prostate Cancer. 1996 http://www.cua.org Accessed 25-10-2004
18. Clinical Guideline. Early detection of prostate cancer. Part III. screening for prostate cancer. Ann Intern Med 1997; 126: 480-4
19. Rose VL. ACP issues guidelines on the early detection of prostate cancer and screening for prostate cancer. Am Fam Physician 1997; 56: 1674-5
20. Royal College of Radiologists Clinical Oncology Information Network - British Association of Urological Surgeons. Guidelineson the Management of Prostate Cancer 1999. www.rcr.ac.uk/ oncologytemplate.asp?PagelD=219. Accessed 25-10-2004
21. Chan EC, Vernon SW, O'Donnell FT, Ahn C, Greisinger A, Aga DW. Informed consent for cancer screening with prostate-specific antigen: how well are men getting the message? Am J Public Health 2003; 93: 779-85
22. Carter HB. Informed consent for prostate-specific antigen screening. Urology 2003; 61: 13-4
23. Foxhall LE, von Eschenbach AC. Counseling patients about prostate cancer screening. Am Fam Physician 2002; 65: 1752-7
24. Gann PH. Informed consent for prostate-specific antigen testing. Urology 2003; 61: 5-6
25. Brawley OW. Informed consent for prostate-specific antigen-based screening. Urology 2003; 61: 10-2
26. Catalona WJ. Informed consent for prostate-specific antigen screening. Urology 2003; 61: 17-9
27. Chan EC, Sulmasy DP. What should men know about prostate-specific antigen screening before giving informed consent? Am J Med 1998; 105: 266-74
28. Collins M. Increasing prostate cancer awareness in African American men. Oncol Nurs Forum 1997; 24: 91-5
29. Farrell MH, Murphy MA, Schneider CE. How underlying patient beliefs can affect physician-patient communication about prostate-specific antigen testing. Eff Clin Pract 2002; 5: 120-9
30. List MA, Sinner M, Chodak GW. Improving knowledge about prostate cancer. The development of an educational program for African-Americans. Prostate Cancer Prostatic Dis 1999; 2: 186-90
31. Sheridan SL, Felix K, Pignone MP, Lewis CL. Information needs of men regarding prostate cancer screening and the effect of a brief decision aid. Patient Educ Couns 2004; 54: 345-51
32. Wilkinson S, List M, Sinner M, Dai L, Chodak G. Educating African-American men about prostate cancer, impact on awareness and knowledge. Urology 2003; 61: 308-13
33. Wolf AM, Nasser JF, Wolf AM, Schorling JB. The impact of informed consent on patient interest in prostate-specific antigen screening. Arch Intern Med 1996; 156: 1333-6
34. Wolf AM, Philbrick JT, Schorling JB. Predictors of interest in prostate-specific antigen screening and the impact of informed consent: what should we tell our patients? Am J Med 1997; 103: 308-14
35. Wolf AM, Schorling JB. Preferences of elderly men for prostate-specific antigen screening and the impact of informed consent. J Gerontol Biol Sci Med Sci 1998; 53: M195-M200
36. Frosch DL, Kaplan RM, Felitti V. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001; 16: 391-8
37. Flood AB, Wennberg JE, Nease RFJ, Fowler FJJ, Ding J, Hynes LM. The importance of patient preference in the decision to screen for prostate cancer. Prostate Patient Outcomes Research Team. J Gen Intern Med 1996; 11: 342-9
38. Volk RJ, Cass AR, Spann SJ. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med 1999; 8: 333-40
39. Davison BJ, Kirk P, Degner LF, Hassard TH. Information and patient participation in screening for prostate cancer. Patient Educ Couns 1999; 37: 255-63
40. Gattellari M, Ward JE. Does evidence-based information about screening for prostate cancer enhance consumer decision-making? A randomised controlled trial. J Med Screen 2003; 10: 27-39
41. Schapira MM, VanRuiswyk J. The effect of an illustrated pamphlet decision-aid on the use of prostate cancer screening tests. J Fam Pract 2000; 49: 418-24
42. Wilt TJ, Paul J, Murdoch M, Nelson D, Nugent S, Rubins HB. Educating men about prostate cancer screening. A randomized trial of a mailed pamphlet. Eff Clin Pract 2001; 4: 112-20
43. Frosch DL, Kaplan RM, Felitti VJ. A randomized controlled trial comparing internet and video to facilitate patient education for men considering the prostate specific antigen test. J Gen Intern Med 2003; 18: 781-7
44. Volk RJ, Spann SJ, Cass AR, Hawley ST. Patient education for informed decision making about prostate cancer screening: a randomized controlled trial with 1-year follow-up. Ann Fam Med 2003; 1: 22-8
45. Partin MR, Nelson D, Radosevich D et al. Randomized trial examining the effect of two prostate cancer screening educational interventions on patient knowledge, preferences, and behaviors. J Gen Intern Med 2004; 19: 835-42
46. Radosevich DM, Partin MR, Nugent S et al. Measuring patient knowledge of the risks and benefits of prostate cancer screening. Patient Educ Couns 2004; 54: 143-52
47. Essink Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schroder FH. Short-term effects of population-based screening for prostate cancer on health-related quality of life. J Natl Cancer Inst 1998; 90: 925-31
48. Cantor SB, Volk RJ, Cass AR, Qilani J, Spann SJ. Psychological benefits of prostate cancer screening: the role of reassurance. Health Expect 2002; 5: 104-13
49. Taylor KL, Shelby R, Kerner J, Redd W, Lynch J. Impact of undergoing prostate carcinoma screening on prostate carcinoma-related knowledge and distress. Cancer 2002; 95: 1037-44
50. Taylor KL, DiPlacido J, Redd WH, Faccenda K, Greer L, Perlmutter A. Demographics, family histories, and psychological characteristics of prostate carcinoma screening participants. Cancer 1999; 85: 1305-12
51. Stone AA, Mezzacappa ES, Donatone BA, Gonder M. Psychosocial stress and social support are associated with prostate-specific antigen levels in men: results from a community screening program. Health Psychol 1999; 18: 482-6
52. Cohen L, Fouladi RT, Babaian RJ et al. Cancer worry is associated with abnormal prostate-specific antigen levels in men participating in a community screening program. Cancer Epidemiol Biomarkers Prevention 2003; 12: 610-7
53. Gustafsson O, Theorell T, Norming U, Perski A, Ohstrom M, Nyman CR. Psychological reactions in men screened for prostate cancer. Br J Urol 1995; 75: 631-6
54. Bratt O, Kristoffersson U, Lundgren R, Olsson H. Sons of men with prostate cancer: their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology 1997; 50: 360-5
55. Bratt O, Damber JE, Emanuelsson M et al. Risk perception, screening practice and interest in genetic testing among unaffected men in families with hereditary prostate cancer. Eur J Cancer 2000; 36: 235-41
56. Bratt O, Emanuelsson M, Gronberg H. Psychological aspects of screening in families with hereditary prostate cancer. Scand J Urol Nephral 2003; 37: 5-9
57. Cormier L, Guillemin F, Valeri A et al. Impact of prostate cancer screening on health-related quality of life in at-risk families. Urology 2002; 59: 901-6
58. Cockburn J, De Luise T, Hurley S, Clover K. Development and validation of the PCQ. A questionnaire to measure the psychological consequences of screening mammography. Soc Sci Med 1992; 34: 1129-34
59. Ong GJ, Austoker J, Brett J, Brouwer A, Michell M. Reducing the adverse psychological sequelae of women who are called back for further investigations of breast screening: new results of multicentre studies in the UK. Psycho-Oncology 1997; 6: 237-8
60. Taylor KL, Turner RO, Davis JL et al. Improving knowledge of the prostate cancer screening dilemma among African American men: an academic-community partnership in Washington, DC. Public Health Rep 2001; 116: 590-8